Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2663 - The bacterial receptor NOD2 mediates LGR5+ intestinal stem cells protection against irradiation via mitophagy activation

Date

28 Sep 2019

Session

Poster Display session 1

Presenters

Antonin Levy

Citation

Annals of Oncology (2019) 30 (suppl_5): v1-v24. 10.1093/annonc/mdz238

Authors

A. Levy1, E. Deutsch2, P. Sansonetti3, G. Nigro3

Author affiliations

  • 1 Radiation Oncology, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 2 Radiation Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 3 Molecular Microbial Pathogenesis Unit, Institut Pasteur, 75015 - Paris/FR
More

Resources

Abstract 2663

Background

The NOD2 agonist muramyl-dipeptide (MDP), a peptidoglycan motif common to all bacteria, supports LGR5+ intestinal stem cells (ISCs) survival through NOD2 activation upon an otherwise lethal oxidative-stress-mediated signal. Yet the underlying protective mechanisms remains unknown.

Methods

Irradiation was used as stressor and primarily murine-derived intestinal organoids as a model system.

Results

MDP induced a strong reduction of total and mitochondrial reactive oxygen species (ROS) within ISCs, which was associated with mitophagy induction. ATG16L1 KO and NOD2 KO organoids did not benefit from the MDP-induced cytoprotection. We showed the MDP-dependent induction of ISC mitophagy upon stress in vivo.

Conclusions

In LGR5+ ISCs, NOD2 allows irradiation-generated ROS clearance through ATG16L1-activated mitophagy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

This work was supported by European Research Council (ERC) advanced grant 339579-DECRYPT to P.J.S and by French National Research Agency (ANR) grant 17-CE14-0022 (i-Stress) to P.S.. A.L. was personally funded by: i) Poste d’Accueil INSERM and ii) Soutien pour la formation à la recherche translationnelle en cancérologie (ITMO Cancer, INCa - Plan Cancer 2014-2019, allocation number: ASC17040JSA).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings